File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma

TitleOverall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma
Authors
Issue Date2005
Citation
Journal of the National Cancer Institute, 2005, v. 97, n. 7, p. 536-539 How to Cite?
AbstractThis phase III randomized study compared concurrent cisplatin-radiotherapy (CRT) versus radiotherapy (RT) alone in patients with locoregionally advanced nasopharyngeal carcinoma. A total of 350 patients were randomly assigned to receive external RT alone or concurrently with cisplatin at a dosage of 40 mg/m 2 weekly. The primary endpoint was overall survival, and the median follow-up was 5.5 years. The 5-year overall survival was 58.6% (95% confidence interval [CI] = 50.9% to 66.2%) for the RT arm and 70.3% (95% CI = 63.4% to 77.3%) for the CRT arm. In Cox regression analysis adjusted for T stage, age, and overall stage, the difference in overall survival was statistically significantly in favor of concurrent CRT (P = .049, hazard ratio [HR] = 0.71 [95% CI = 0.5 to 1.0]). Subgroup analysis demonstrated that there was no difference between overall survival in the arms for T1 /T2 stage (P = .74, HR = 0.93 [95% CI = 0.59 to 1.4] ), whereas there was a difference between the arms for T3/T4 stage (P = .013, HR = 0.51 [95% CI = 0.3 to 0.88]), favoring the CRT arm. The regimen of weekly concurrent CRT is a promising standard treatment strategy for locoregionally advanced nasopharyngeal carcinoma patients. © Oxford University Press 2005, all rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/251603
ISSN
2020 Impact Factor: 13.506
2015 SCImago Journal Rankings: 6.192
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, Anthony T.C.-
dc.contributor.authorLeung, S. F.-
dc.contributor.authorNgan, Roger K.C.-
dc.contributor.authorTeo, Peter M.L.-
dc.contributor.authorLau, W. H.-
dc.contributor.authorKwan, W. H.-
dc.contributor.authorHui, Edwin P.-
dc.contributor.authorYiu, H. Y.-
dc.contributor.authorYeo, Winnie-
dc.contributor.authorCheung, F. Y.-
dc.contributor.authorYu, K. H.-
dc.contributor.authorChiu, K. W.-
dc.contributor.authorChan, D. T.-
dc.contributor.authorMok, Tony S.K.-
dc.contributor.authorYau, Stephen-
dc.contributor.authorYuen, K. T.-
dc.contributor.authorMo, Frankie K.F.-
dc.contributor.authorLai, Maria M.P.-
dc.contributor.authorMa, Brigette B.Y.-
dc.contributor.authorKam, Michael K.M.-
dc.contributor.authorLeung, Thomas W.T.-
dc.contributor.authorJohnson, Philip J.-
dc.contributor.authorChoi, Peter H.K.-
dc.contributor.authorZee, Benny C.Y.-
dc.date.accessioned2018-03-08T05:00:26Z-
dc.date.available2018-03-08T05:00:26Z-
dc.date.issued2005-
dc.identifier.citationJournal of the National Cancer Institute, 2005, v. 97, n. 7, p. 536-539-
dc.identifier.issn0027-8874-
dc.identifier.urihttp://hdl.handle.net/10722/251603-
dc.description.abstractThis phase III randomized study compared concurrent cisplatin-radiotherapy (CRT) versus radiotherapy (RT) alone in patients with locoregionally advanced nasopharyngeal carcinoma. A total of 350 patients were randomly assigned to receive external RT alone or concurrently with cisplatin at a dosage of 40 mg/m 2 weekly. The primary endpoint was overall survival, and the median follow-up was 5.5 years. The 5-year overall survival was 58.6% (95% confidence interval [CI] = 50.9% to 66.2%) for the RT arm and 70.3% (95% CI = 63.4% to 77.3%) for the CRT arm. In Cox regression analysis adjusted for T stage, age, and overall stage, the difference in overall survival was statistically significantly in favor of concurrent CRT (P = .049, hazard ratio [HR] = 0.71 [95% CI = 0.5 to 1.0]). Subgroup analysis demonstrated that there was no difference between overall survival in the arms for T1 /T2 stage (P = .74, HR = 0.93 [95% CI = 0.59 to 1.4] ), whereas there was a difference between the arms for T3/T4 stage (P = .013, HR = 0.51 [95% CI = 0.3 to 0.88]), favoring the CRT arm. The regimen of weekly concurrent CRT is a promising standard treatment strategy for locoregionally advanced nasopharyngeal carcinoma patients. © Oxford University Press 2005, all rights reserved.-
dc.languageeng-
dc.relation.ispartofJournal of the National Cancer Institute-
dc.titleOverall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1093/jnci/dji084-
dc.identifier.pmid15812080-
dc.identifier.scopuseid_2-s2.0-15944417086-
dc.identifier.volume97-
dc.identifier.issue7-
dc.identifier.spage536-
dc.identifier.epage539-
dc.identifier.isiWOS:000231113100016-
dc.identifier.issnl0027-8874-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats